WHO Treatment Guidelines for Drug-Resistant Tuberculosis, 2016 Update
- PMID: 27748093
- Bookshelf ID: NBK390455
WHO Treatment Guidelines for Drug-Resistant Tuberculosis, 2016 Update
Excerpt
The WHO treatment guidelines for drug-resistant tuberculosis (2016 update) contains policy recommendations on priority areas in the treatment of drug-resistant tuberculosis. The revision is in accordance with the WHO requirements for the formulation of evidence-informed policy.
The main novelties of the 2016 WHO guidelines are:
a shorter MDR-TB treatment regimen is recommended under specific conditions;
medicines used in the design of conventional MDR-TB treatment regimens are now reclassified to reflect updates in the evidence on their effectiveness and safety;
specific recommendations are made on the treatment of children with rifampicin-resistant or MDR-TB based on a first-ever individual patient data meta-analysis;
recommendations on the role of surgery in MDR-TB case management are included.
Copyright © World Health Organization 2016.
Sections
- Abbreviations & acronyms
- Acknowledgements
- Declarations of interest
- Executive summary
- Introduction
- Methods
- WHO policy recommendations
- References
-
Appendix 1 Agenda for the Guidelines Development Group meeting on the
WHO treatment guidelines for drug-resistant TB 2016 update , 9–11 November 2015 -
Appendix 2 Experts involved in the development of the
WHO treatment guidelines for drug-resistant TB 2016 update - Appendix 3 PICO questions
- Appendix 4 GRADE tables
- Appendix 5 Evidence to decision tables
- Appendix 6 Summaries of unpublished data used for the recommendations
Publication types
LinkOut - more resources
Full Text Sources
Medical
